Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613427 | 0.98 | GPR84 (0.38) | HIF1AGSTK1GPR84TSHRSLC22A6 | |
| SCHEMBL7611023 | 0.93 | HIF1A (0.39) | HIF1AGSTK1GPR84TSHRSLC22A6 | |
| SCHEMBL8048193 | 0.85 | TSHR (0.45) | GPR84TSHRFAAHTRPV1 | |
| SCHEMBL7617453 | 0.84 | SLC22A6 (0.38) | HIF1AGPR84TSHRSLC22A6CACNA2D1 | |
| SCHEMBL8065335 | 0.84 | TSHR (0.44) | GPR84TSHRFAAHTRPV1 | |
| SCHEMBL11546916 | 0.83 | GSTK1 (0.36) | GSTK1GPR84SLC22A6CACNA2D1CACNB3 | |
| SCHEMBL7615140 | 0.81 | MAPT (0.52) | GSTK1GPR84TSHR | |
| SCHEMBL7619319 | 0.79 | MAPT (0.55) | GSTK1GPR84TSHR | |
| SCHEMBL14798190 | 0.79 | GPR84 (0.60) | GPR84TSHRSLC22A6FAAH | |
| SCHEMBL15541796 | 0.79 | BHMT (0.40) | HIF1AGPR84TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433150-B2 | Anthracycline analogues bearing latent alkylating substituents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-08-13 | — | — | US | disclosed |
| US-20010053845-A1 | Anthracycline analogues bearing latent alkylating substituents | BOARD OF REGENTS | 2001-12-20 | — | — | US | disclosed |
| US-6284737-B1 | ANTICARCER AGENTS | PRO-NEURON, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0555358-B1 | ANTHRACYCLINE ANALOGUES BEARING LATENT ALKYLATING SUBSTITUENTS | UNIV TEXAS (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0555358-A1 | ANTHRACYCLINE ANALOGUES BEARING LATENT ALKYLATING SUBSTITUENTS. | UNIV TEXAS (US) | 1993-08-18 | — | — | EP | disclosed |
| US-5196522-A | Antitumor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1992007866-A1 | ANTHRACYCLINE ANALOGUES BEARING LATENT ALKYLATING SUBSTITUENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053845-A1 | Anthracycline analogues bearing latent alkylating substituents | BCR, MCL1, NCL | HIF1A 3032/4885GSTK1 910/4885GPR84 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.